All In Biotech

Drug Trial Radar · NCT01797965

Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019

A Multicenter, Open-Label, Extension Study to Evaluate the Long Term Safety and Efficacy of BIIB019, Daclizumab High Yield Process (DAC HYP), Monotherapy in Subjects With Multiple Sclerosis Who Have Completed Study 205MS301

Last checked: Nov 20, 2026Latest source record: Dec 4, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

1,501

Actual

Start

Feb 15, 2013

Primary completion

Sep 24, 2018

Study completion Sep 24, 2018

Sponsor

Lead sponsor
BiogenBiogen (BIIB)
Sponsor type
Industry
Collaborators
AbbVie
First posted
Feb 25, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of the study is to assess the safety and tolerability of long-term treatment with BIIB019 (Daclizumab High Yield Process; DAC HYP) monotherapy in participants with relapsing remitting multiple sclerosis (RRMS) who completed Study 205MS301 (NCT01064401), Study 205MS203 (NCT01051349) or Study 205MS302 (NCT01462318). Secondary objectives of this study in this study population are as follows: To describe MS-related outcomes, including MS relapse, disability progression, MS lesion formation, and participant-reported impact of MS, following long-term treatment with DAC HYP To assess the long-term immunogenicity of DAC HYP administered by prefilled syringe (PFS) To assess the safety, tolerability, and efficacy of switching to DAC HYP in participants previously on long-term treatment with interferon β-1a (Avonex) in Study 205MS301(NCT01064401).

Conditions

  • Relapsing-Remitting Multiple Sclerosis
  • Multiple Sclerosis

Interventions

  • BIIB019 (Daclizumab)Drug

    Participants will receive open-label treatment with BIIB019 150 mg subcutaneous injection every 4 weeks for up to 5 years.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: First dose of study drug in Study 303 to within 180 days of last dose (up to approximately 5.5 years)

Locations

222 sites in 27 countries. Site status is shown where the registry gives one.

  • Research Site

    Phoenix, Arizona

  • Research Site

    Phoenix, Arizona

  • Research Site

    Tucson, Arizona

  • Research Site

    Little Rock, Arkansas

  • Research Site

    La Jolla, California

  • Research Site

    Aurora, Colorado

  • Research Site

    Centennial, Colorado

  • Research Site

    Naples, Florida

  • Research Site

    Pompano Beach, Florida

  • Research Site

    Atlanta, Georgia

  • Research Site

    Fort Wayne, Indiana

  • Research Site

    Indianapolis, Indiana

  • Research Site

    Kansas City, Kansas

  • Research Site

    Lexington, Kentucky

  • Research Site

    Wellesley, Massachusetts

  • Research Site

    Worcester, Massachusetts

  • Research Site

    Farmington Hills, Michigan

  • Research Site

    Lebanon, New Hampshire

  • Research Site

    Albuquerque, New Mexico

  • Research Site

    Buffalo, New York

  • Research Site

    Latham, New York

  • Research Site

    New York, New York

  • Research Site

    New York, New York

  • Research Site

    Rochester, New York

  • Research Site

    Charlotte, North Carolina

  • Research Site

    Raleigh, North Carolina

  • Research Site

    Winston-Salem, North Carolina

  • Research Site

    Dayton, Ohio

  • Research Site

    Medford, Oregon

  • Research Site

    Portland, Oregon

  • Research Site

    Allentown, Pennsylvania

  • Research Site

    Pittsburgh, Pennsylvania

  • Research Site

    Cordova, Tennessee

  • Research Site

    Franklin, Tennessee

  • Research Site

    Knoxville, Tennessee

  • Research Site

    Round Rock, Texas

  • Research Site

    Henrico, Virginia

  • Research Site

    Tacoma, Washington

  • Research Site

    Milwaukee, Wisconsin

  • Research Site

    Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina

Showing 40 of 222 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.